Free Trial

Dianthus Therapeutics (DNTH) Competitors

Dianthus Therapeutics logo
$20.80 -0.59 (-2.76%)
Closing price 07/30/2025 04:00 PM Eastern
Extended Trading
$19.48 -1.33 (-6.37%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DNTH vs. ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, RARE, OGN, APLS, and IBRX

Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

Dianthus Therapeutics vs. Its Competitors

Alvotech (NASDAQ:ALVO) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

47.5% of Dianthus Therapeutics shares are held by institutional investors. 0.5% of Alvotech shares are held by insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alvotech currently has a consensus target price of $14.00, indicating a potential upside of 50.86%. Dianthus Therapeutics has a consensus target price of $53.00, indicating a potential upside of 154.81%. Given Dianthus Therapeutics' higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dianthus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Alvotech has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

In the previous week, Alvotech had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 3 mentions for Alvotech and 2 mentions for Dianthus Therapeutics. Alvotech's average media sentiment score of 1.29 beat Dianthus Therapeutics' score of 0.94 indicating that Alvotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dianthus Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dianthus Therapeutics has lower revenue, but higher earnings than Alvotech. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.98M5.69-$231.86M$0.3725.08
Dianthus Therapeutics$6.24M107.20-$84.97M-$2.88-7.22

Alvotech has a net margin of 16.42% compared to Dianthus Therapeutics' net margin of -1,544.23%. Dianthus Therapeutics' return on equity of -29.26% beat Alvotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech16.42% -36.37% 12.70%
Dianthus Therapeutics -1,544.23%-29.26%-27.87%

Summary

Dianthus Therapeutics beats Alvotech on 8 of the 15 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNTH vs. The Competition

MetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$687.90M$3.03B$5.65B$9.53B
Dividend YieldN/A2.39%4.71%4.03%
P/E Ratio-7.2224.3630.2320.54
Price / Sales107.20322.48449.5898.31
Price / CashN/A42.5936.0158.40
Price / Book1.758.278.345.74
Net Income-$84.97M-$55.06M$3.25B$259.12M
7 Day Performance-4.54%-3.45%-2.17%-2.61%
1 Month Performance11.65%13.91%7.94%8.58%
1 Year Performance-30.15%3.45%36.42%15.07%

Dianthus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNTH
Dianthus Therapeutics
1.0875 of 5 stars
$20.80
-2.8%
$53.00
+154.8%
-28.5%$687.90M$6.24M-7.2280Upcoming Earnings
ALVO
Alvotech
2.8957 of 5 stars
$8.64
+0.1%
$16.00
+85.2%
-21.4%$2.60B$491.98M23.351,032Positive News
MIRM
Mirum Pharmaceuticals
3.8153 of 5 stars
$51.95
+0.0%
$65.50
+26.1%
+26.8%$2.57B$336.89M-32.27140Positive News
Upcoming Earnings
CPRX
Catalyst Pharmaceuticals
4.9249 of 5 stars
$21.01
-0.1%
$32.83
+56.3%
+23.9%$2.57B$491.73M13.3880Positive News
Upcoming Earnings
GMTX
Gemini Therapeutics
N/A$57.77
0.0%
N/A+36.5%$2.50BN/A-57.7730High Trading Volume
AMRX
Amneal Pharmaceuticals
3.1655 of 5 stars
$7.91
-0.8%
$11.60
+46.6%
+11.8%$2.50B$2.83B-197.708,100
NAMS
NewAmsterdam Pharma
3.4921 of 5 stars
$22.56
+1.6%
$41.30
+83.1%
+38.6%$2.49B$45.56M-12.004Upcoming Earnings
RARE
Ultragenyx Pharmaceutical
4.4966 of 5 stars
$26.39
+0.3%
$83.64
+216.9%
-39.3%$2.49B$560.23M-4.491,294Analyst Upgrade
Analyst Revision
High Trading Volume
OGN
Organon & Co.
4.7866 of 5 stars
$9.43
-0.4%
$18.00
+91.0%
-54.8%$2.46B$6.40B3.274,000Positive News
Upcoming Earnings
APLS
Apellis Pharmaceuticals
4.3704 of 5 stars
$19.28
-1.0%
$40.00
+107.5%
-51.6%$2.45B$781.37M-10.77770Analyst Forecast
Analyst Revision
IBRX
ImmunityBio
2.1474 of 5 stars
$2.68
-2.5%
$12.25
+357.1%
-51.5%$2.43B$14.74M-4.62590

Related Companies and Tools


This page (NASDAQ:DNTH) was last updated on 7/31/2025 by MarketBeat.com Staff
From Our Partners